Literature DB >> 9039207

Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a.

B Kütting1, G Bonsmann, D Metze, T A Luger, L Cerroni.   

Abstract

We report two patients with low-grade malignant primary cutaneous B cell lymphoma in association with Borrelia burgdorferi infection. Extracutaneous manifestations were ruled out by standard staging procedures. Infection with Borrelia burgdorferi was confirmed by cultivation from lesional skin in both patients. In the first patient skin lesions cleared completely after pulse therapy with cefotaxime, whereas in the second patient antibiotic treatment failed. In this patient, however, skin lesions completely cleared after intralesional injection of interferon alfa-2a. Antibiotic treatment or intralesional injection of interferon alfa-2a should be considered as a first-line treatment of Borrelia burgdorferi-associated primary cutaneous B cell lymphoma before more aggressive conventional therapeutic modalities (e.g., radiation therapy) are applied.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9039207     DOI: 10.1016/s0190-9622(97)80405-7

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  15 in total

1.  Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas.

Authors:  Maurilio Ponzoni; Andrés J M Ferreri; Silvia Mappa; Elisa Pasini; Silvia Govi; Fabio Facchetti; Daniele Fanoni; Alessandra Tucci; Arianna Vino; Claudio Doglioni; Emilio Berti; Riccardo Dolcetti
Journal:  Oncologist       Date:  2011-11-09

Review 2.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

Authors:  Jan A Burger; Paolo Ghia; Andreas Rosenwald; Federico Caligaris-Cappio
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

3.  [31/f with livid erythematous papules and nodules : Preparation for the specialist examination: part 6].

Authors:  Luisa Hellmich
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

Review 4.  Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides.

Authors:  Meenal Kheterpal; Neha Mehta-Shah; Pooja Virmani; Patricia L Myskowski; Alison Moskowitz; Steven M Horwitz
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

Review 5.  Role of the tumor microenvironment in mature B-cell lymphoid malignancies.

Authors:  Nathan H Fowler; Chan Yoon Cheah; Randy D Gascoyne; John Gribben; Sattva S Neelapu; Paolo Ghia; Catherine Bollard; Stephen Ansell; Michael Curran; Wyndham H Wilson; Susan O'Brien; Cliona Grant; Richard Little; Thorsten Zenz; Loretta J Nastoupil; Kieron Dunleavy
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

Review 6.  Role of bacteria in oncogenesis.

Authors:  Alicia H Chang; Julie Parsonnet
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

7.  Murine model for lymphocytic tropism by Borrelia burgdorferi.

Authors:  D W Dorward; R S Larson
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

8.  [Cutaneous marginal zone lymphoma (SALT) and infection with Borrelia burgdorferi].

Authors:  M Fühler; K W Ottmann; M Tronnier
Journal:  Hautarzt       Date:  2010-02       Impact factor: 0.751

9.  Borrelia infection and risk of non-Hodgkin lymphoma.

Authors:  Claudia Schöllkopf; Mads Melbye; Lars Munksgaard; Karin Ekström Smedby; Klaus Rostgaard; Bengt Glimelius; Ellen T Chang; Göran Roos; Mads Hansen; Hans-Olov Adami; Henrik Hjalgrim
Journal:  Blood       Date:  2008-04-18       Impact factor: 22.113

10.  Primary cystic lung light chain deposition disease: a clinicopathologic entity derived from unmutated B cells with a stereotyped IGHV4-34/IGKV1 receptor.

Authors:  Magali Colombat; Hervé Mal; Christiane Copie-Bergman; Jacques Diebold; Diane Damotte; Patrice Callard; Michel Fournier; Jean-Pierre Farcet; Marc Stern; Marie-Hélène Delfau-Larue
Journal:  Blood       Date:  2008-05-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.